Intercept Pharmaceuticals Receives FDA Orphan Drug Designation for the Fixed-Dose Combination of OCA and Bezafibrate for the Treatment of Primary Biliary Cholangitis (PBC)

May 16, 2023

https://www.globenewswire.com/news-release/2023/05/16/2670490/23024/en/Intercept-Pharmaceuticals-Receives-FDA-Orphan-Drug-Designation-for-the-Fixed-Dose-Combination-of-OCA-and-Bezafibrate-for-the-Treatment-of-Primary-Biliary-Cholangitis-PBC.html

Company on track to complete planned interim analyses from two ongoing Phase 2 studies of the OCA-bezafibrate combination in 2023

Results from planned interim analysis of Phase 2 study evaluating the effects of OCA and bezafibrate on serum biomarkers in PBC to be presented at EASL Congress 2023

Read more at globenewswire.com

Related news for (ICPT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.